# DC Migration Study for Newly-Diagnosed GBM

> **NCT02366728** · PHASE2 · COMPLETED · sponsor: **Mustafa Khasraw, MBChB, MD, FRCP, FRACP** · enrollment: 64 (actual)

## Conditions studied

- Glioblastoma
- Astrocytoma, Grade IV
- Giant Cell Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **BIOLOGICAL:** Unpulsed DCs
- **BIOLOGICAL:** Td
- **BIOLOGICAL:** Human CMV pp65-LAMP mRNA-pulsed autologous DCs
- **BIOLOGICAL:** 111In-labeled DCs
- **DRUG:** Temozolomide
- **DRUG:** Saline
- **DRUG:** Basiliximab

## Key facts

- **NCT ID:** NCT02366728
- **Lead sponsor:** Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-12
- **Primary completion:** 2020-10-31
- **Final completion:** 2020-10-31
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366728, "DC Migration Study for Newly-Diagnosed GBM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02366728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*